Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ODI Pharma ABXSAT:ODI +3.25%46 Days Payable is 52.78 as of Mar. 2026, which is 84% below its 10-year median of 328.32. GuruFocus rates XSAT:ODI with a GF Score™ of 46/100 and a GF Value™ of kr9.52 (Significantly Undervalued). Among 927 Drug Manufacturers companies, ODI Pharma AB ranks worse than 66.02% on this metric.
The historical rank and industry rank for ODI Pharma AB's Days Payable or its related term are showing as below:
XSAT:ODI'
s Days Payable Range Over the Past 10 Years
Min: 59.02 Med: 328.32 Max: 428.46
Current: 62.54
During the past 7 years, ODI Pharma AB's highest Days Payable was 428.46. The lowest was 59.02. And the median was 328.32.
XSAT:ODI's Days Payable is ranked worse than 66.02% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs XSAT:ODI: 62.54
ODI Pharma AB's Days Payable
declined
from Mar. 2025 (88.35) to Mar. 2026 (52.78).
It may suggest that ODI Pharma ABaccelerated paying its suppliers.
ODI Pharma AB Days Payable Related Terms
ODI Pharma AB Days Payable Historical Data
* Premium members only.
The historical data trend for ODI Pharma AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:ODI vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ODI Pharma AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ODI Pharma AB Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ODI Pharma AB's Days Payable distribution charts can be found below:
* The bar in red indicates where ODI Pharma AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ODI Pharma AB's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ODI Pharma AB (XSAT:ODI) has a Days Payable of 52.78 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ODI Pharma AB and its competitors. This is 84% below median its historical median of 328.32. Over the past decade, ODI Pharma AB's Days Payable has ranged from 59.02 to 428.46. According to the industry distribution chart, ODI Pharma AB ranks #612 out of 927 companies in the Drug Manufacturers industry, placing it in the top 66%.
Is ODI Pharma AB's Days Payable too high?
ODI Pharma AB's current Days Payable of 52.78 is 84% below median its 10-year median of 328.32. Over the past 10 years, this metric has ranged from a low of 59.02 to a high of 428.46. The Drug Manufacturers industry median Days Payable is 90.38. ODI Pharma AB's value of 52.78 is 41.6% below this industry median. Based on the distribution chart, ODI Pharma AB ranks #612 out of 927 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ODI Pharma AB ranks #612 out of 927 companies for Days Payable. This places ODI Pharma AB in the lower half of its industry. The industry median Days Payable is 90.38. ODI Pharma AB's value of 52.78 is 41.6% below this benchmark. Historically, ODI Pharma AB's own Days Payable has ranged from 59.02 to 428.46 over the past decade. While the company's 10-year median is 328.32 vs. the industry median of 90.38, ODI Pharma AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ODI Pharma AB's current Days Payable of 52.78 is 41.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ODI Pharma AB and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ODI Pharma AB's current Days Payable is 52.78, which is 84% below median its own 10-year median of 328.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.52, compared to a current price of kr2.54 — trading 73.3% below its estimated fair value. The current Days Payable is 52.78, which is 84% below median its 10-year median of 328.32 and 41.6% below the Drug Manufacturers industry median of 90.38. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current Days Payable is 52.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?
Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued.
The current stock price of kr2.54 is trading 73.3% below its estimated GF Value™ of kr9.52.
GuruFocus considers ODI Pharma AB to be Significantly Undervalued.
Key valuation signals for XSAT:ODI:
Days Payable: 52.78 (84% below median its 10-year median of 328.32)
GF Value™: kr9.52 vs. price of kr2.54 (73.3% below fair value)
Industry Position: 41.6% below the Drug Manufacturers median (#612 of 927)
No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ODI has been successfully added to your 
